Genomics of Hematologic Cancers (Volume II)
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 30 November 2024 | Viewed by 55
Special Issue Editors
Interests: haematological neoplasms; multiple myeloma; mastocytosis; biomarkers; molecular biology; genetics; epigenetics; predictive factors; prognostic factors; targeted therapy
Special Issues, Collections and Topics in MDPI journals
Interests: haematological neoplasms; multiple myeloma; leukemia; lymphoma; mastocytosis; biomarkers; molecular biology; genetics; epigenetics; predictive factors; prognostic factors; targeted therapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Hematologic malignancies account for 10% of all cancers around the world and have become more frequent over the past years. Despite the huge progress associated with the improvements in hematologic molecular diagnostics and the development of targeted therapies such as kinase inhibitors, monoclonal antibodies, CART-cells, and bispecific antibodies, most hematologic cancers remain incurable diseases.
Applying genomic analysis based on high-throughput sequencing technologies has been rapidly expanding our understanding of cancer’s origin and complexity, providing us with more reliable information on its progression, metastases, and survival. Genome sequencing can provide information on the full spectrum of genetic mutations that trigger or contribute to cancer development and how cancer evolves in response to treatments.
In this way, cancer genome profiling is currently widely applied to routine clinical practice and has enabled the detection of predictive biomarkers of response for treatment.
This Special Issue is devoted to the application of genomics in identifying new cancer targets and developing new targeted therapies in hematologic cancers.
Dr. Aneta Szudy-Szczyrek
Prof. Dr. Marek Hus
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- genomics
- cancer
- hematological malignancy
- leukemia
- lymphoma
- myeloma
- whole-genome sequencing
- precision cancer medicine
- target gene
- targeted therapy
- personalized medicine
